The new hub, which brings Avantor solutions closer to regional customers and strengthens global supply chain capabilities, will be fully operational early next year
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
It will showcase the company’s latest technologies in robotics, digital health and orthopaedic implants
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Subscribe To Our Newsletter & Stay Updated
